MarketCapExport financials
Pacific Biosciences of California (PACB)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Pacific Biosciences of California Balance Sheet 2025-2008 | PACB
Brief balance sheet overview of Pacific Biosciences of California
The comparison uses five available annual reports from the 2021–2025 interval.
Assets declined from $2 billion to $784.1 million, or -60.9%. The contraction calls for context such as disposals, restructuring or weaker operations.
Liabilities grew faster than assets: -36% versus -60.9%. A substantial part of expansion was externally funded.
The equity ratio equals 0.7%, with a starting level of 39.4%. Stable cash flow is important under this structure.
The period ended with net cash: net debt stood at -$6.7 million. This supports financial flexibility.
Cash equals 8.1% of the balance sheet, compared with 23% five periods ago. This is the readily available cushion.
The balance sheet carries negative retained earnings of -$2.7 billion. The figure may result from accumulated losses or an active capital return policy.
What the balance sheet shows
Taken together, Pacific Biosciences of California's balance sheet indicators point to elevated risk. Asset growth does not offset weak funding sources.
Annual Balance Sheet Pacific Biosciences of California
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-6.67 M | -30.4 M | -139 M | 580 M | -403 M | -39.6 M | 2.12 M | 79.3 M | 43.5 M | 54.6 M | 30 M | 42.6 M | 73.2 M | -43.8 M | -55.9 M | -145 M | - | - |
Long Term Debt |
56.6 M | 14.9 M | 31.6 M | 897 M | 50 M | 37.7 M | 15.9 M | 14.7 M | 13.6 M | 16.1 M | 14.9 M | 14.1 M | 13.3 M | - | - | 2.93 M | - | - |
Long Term Debt Current |
448 K | 10 M | 9.59 M | 8.89 M | 7.71 M | 4.33 M | 3.84 M | - | - | - | - | - | - | 173 K | 140 K | 110 K | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 43.9 M | 29.3 M | 29.3 M | 19.4 M | 19.4 M | 38.1 M | 44.4 M | 5.56 M | 7.48 M | - | - | - |
Total Current Liabilities |
72.8 M | 66.3 M | 95 M | 263 M | 71.7 M | 38.5 M | 49.2 M | 26.9 M | 28.6 M | 33.8 M | 38.2 M | 31.5 M | 22.6 M | 14.7 M | 19.4 M | 20.8 M | - | - |
Total Liabilities |
779 M | 754 M | 1.04 B | 1.2 B | 1.22 B | 78.5 M | 93.1 M | 56.2 M | 58 M | 53.2 M | 57.6 M | 69.6 M | 67 M | 20.3 M | 26.9 M | 25.9 M | - | - |
Deferred Revenue |
15.9 M | 13.9 M | 16.3 M | 30.5 M | 11 M | 10.3 M | 7.61 M | 6.54 M | 6.32 M | 7.13 M | 17.6 M | 12.9 M | 11.7 M | 4.06 M | 6.58 M | 3.22 M | - | - |
Retained Earnings |
-2.7 B | -2.15 B | -1.84 B | -1.53 B | -1.22 B | - | -1.07 B | -982 M | -880 M | -788 M | -713 M | -681 M | -615 M | -536 M | -442 M | -332 M | - | - |
Total Assets |
784 M | 1.26 B | 1.75 B | 1.77 B | 2.01 B | 414 M | 148 M | 170 M | 144 M | 138 M | 131 M | 125 M | 136 M | 130 M | 218 M | 306 M | - | - |
Cash and Cash Equivalents |
63.7 M | 55.4 M | 180 M | 325 M | 461 M | 81.6 M | 29.6 M | 18.8 M | 16.5 M | 16.8 M | 33.6 M | 36.4 M | 26.4 M | 46.5 M | 58.9 M | 148 M | 89.2 M | 78.5 M |
Book Value |
5.35 M | 507 M | 701 M | 563 M | 791 M | 335 M | 54.9 M | 114 M | 86.1 M | 84.7 M | 73.5 M | 54.9 M | 69.2 M | 109 M | 191 M | 280 M | - | - |
Total Shareholders Equity |
5.35 M | 507 M | 701 M | 563 M | 791 M | 335 M | 54.9 M | 114 M | 86.1 M | 84.7 M | 73.5 M | 54.9 M | 69.2 M | 109 M | 191 M | 280 M | -177 M | -93.4 M |
All numbers in USD currency
Quarterly Balance Sheet Pacific Biosciences of California
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
60.4 M | 59 M | 54.3 M | 52.1 M | 50.5 M | 14.9 M | - | - | 29 M | 31.6 M | 34.1 M | 36.6 M | 897 M | 41.1 M | 897 M | 896 M | 896 M | 896 M | 896 M | 896 M | 896 M | 37.7 M | 37.7 M | 37.7 M | 37.7 M | 15.9 M | 15.5 M | 15.2 M | 14.9 M | 14.7 M | 14.4 M | 14.1 M | 13.9 M | 13.6 M | - | - | - | 16.1 M | - | - | - | - | - | - | - | 14.1 M | - | - | - | 13.3 M | - | - | 2.56 M | 2.61 M | 2.66 M | 2.7 M | 2.75 M | 2.79 M | 2.79 M | 2.79 M | 2.79 M |
Total Liabilities |
785 M | 780 M | 767 M | 764 M | 769 M | 754 M | - | - | 1.02 B | 1.04 B | 1.13 B | 1.21 B | 1.2 B | 1.2 B | 1.19 B | 1.19 B | 1.2 B | 1.22 B | 1.19 B | 988 M | 972 M | 78.5 M | 78.5 M | 78.5 M | 78.5 M | 93.1 M | 93.1 M | 93.1 M | 93.1 M | 56.2 M | 56.2 M | 56.2 M | 56.2 M | 58 M | 58 M | 58 M | 58 M | 53.2 M | 53.2 M | 53.2 M | 53.2 M | 57.6 M | 57.6 M | 57.6 M | 57.6 M | 69.4 M | 69.6 M | 69.6 M | 69.6 M | 67 M | 67 M | 67 M | 67 M | 20.3 M | 20.3 M | 20.3 M | 20.3 M | 26.9 M | 26.9 M | 26.9 M | 26.9 M |
Deferred Revenue |
16.1 M | 16.3 M | 16 M | 14.9 M | 15.2 M | 13.9 M | - | - | 17.3 M | 16.3 M | 22.4 M | 25 M | 30.9 M | 30.5 M | 30.7 M | 32.1 M | 12.7 M | 11 M | 9.77 M | 9.53 M | 9.61 M | 8.72 M | 8.72 M | 8.72 M | 8.72 M | 7.61 M | 7.61 M | 7.61 M | 7.61 M | 6.54 M | 6.54 M | 6.54 M | 6.54 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.4 M | 3.35 M | 2.96 M | 3.38 M | 3.56 M | 3.38 M | 3.38 M | 4.24 M | 4.24 M | 4.24 M | 4.24 M |
Retained Earnings |
-2.75 B | -2.7 B | -2.65 B | -2.62 B | -2.58 B | -2.15 B | - | - | -1.92 B | -1.84 B | -1.76 B | -1.69 B | -1.62 B | -1.53 B | -1.45 B | -1.37 B | -1.3 B | -1.22 B | -1.15 B | -1.17 B | -1.12 B | -1.04 B | -1.04 B | -1.04 B | -1.04 B | -1.07 B | -1.07 B | -1.07 B | -1.07 B | -982 M | -982 M | -982 M | -982 M | -880 M | -880 M | -880 M | -880 M | -788 M | -788 M | -788 M | -788 M | -713 M | -713 M | -713 M | -713 M | -681 M | -681 M | -681 M | -681 M | -615 M | -615 M | -615 M | -615 M | -536 M | -536 M | -536 M | -536 M | -442 M | -442 M | -442 M | -442 M |
Total Assets |
752 M | 782 M | 803 M | 825 M | 861 M | 1.26 B | - | - | 1.67 B | 1.75 B | 1.9 B | 1.85 B | 1.9 B | 1.77 B | 1.82 B | 1.88 B | 1.94 B | 2.01 B | 2.03 B | 1.25 B | 1.25 B | 414 M | 414 M | 414 M | 414 M | 148 M | 148 M | 148 M | 148 M | 170 M | 170 M | 170 M | 170 M | 144 M | 144 M | 144 M | 144 M | 138 M | 138 M | 138 M | 138 M | 131 M | 131 M | 131 M | 131 M | 124 M | 125 M | 125 M | 125 M | 136 M | 136 M | 136 M | 136 M | 130 M | 130 M | 130 M | 130 M | 218 M | 218 M | 218 M | 218 M |
Cash and Cash Equivalents |
61 M | 56.3 M | 56.5 M | 54.8 M | 58.5 M | 55.4 M | 78 M | 99.5 M | 76.6 M | 180 M | 386 M | 209 M | 354 M | 325 M | 304 M | 310 M | 429 M | 461 M | 425 M | 460 M | 932 M | 81.6 M | 81.6 M | 81.6 M | 81.6 M | 29.6 M | 29.6 M | 29.6 M | 29.6 M | 18.8 M | 18.8 M | 18.8 M | 18.8 M | 16.5 M | 16.5 M | 16.5 M | 16.5 M | 16.8 M | 16.8 M | 16.8 M | 16.8 M | 33.6 M | 33.6 M | 33.6 M | 33.6 M | 36.4 M | 36.4 M | 36.4 M | 36.4 M | 26.4 M | 26.4 M | 26.4 M | 26.4 M | 46.5 M | 46.5 M | 46.5 M | 46.5 M | 58.9 M | 58.9 M | 58.9 M | 58.9 M |
Book Value |
-33.2 M | 2.37 M | 36.1 M | 61.5 M | 91.6 M | 507 M | - | - | 649 M | 701 M | 764 M | 642 M | 692 M | 563 M | 627 M | 682 M | 735 M | 791 M | 841 M | 258 M | 281 M | 335 M | 335 M | 335 M | 335 M | 54.9 M | 54.9 M | 54.9 M | 54.9 M | 114 M | 114 M | 114 M | 114 M | 86.1 M | 86.1 M | 86.1 M | 86.1 M | 84.7 M | 84.7 M | 84.7 M | 84.7 M | 73.5 M | 73.5 M | 73.5 M | 73.5 M | 54.9 M | 54.9 M | 54.9 M | 54.9 M | 69.2 M | 69.2 M | 69.2 M | 69.2 M | 109 M | 109 M | 109 M | 109 M | 191 M | 191 M | 191 M | 191 M |
Total Shareholders Equity |
-33.2 M | 2.37 M | 36.1 M | 61.5 M | 91.6 M | 507 M | 453 M | 493 M | 649 M | 701 M | 764 M | 642 M | 692 M | 563 M | 627 M | 682 M | 735 M | 791 M | 841 M | 258 M | 281 M | 335 M | 335 M | 335 M | 335 M | 54.9 M | 54.9 M | 54.9 M | 54.9 M | 114 M | 114 M | 114 M | 114 M | 86.1 M | 86.1 M | 86.1 M | 86.1 M | 84.7 M | 84.7 M | 84.7 M | 84.7 M | 73.5 M | 73.5 M | 73.5 M | 73.5 M | 54.9 M | 54.9 M | 54.9 M | 54.9 M | 69.2 M | 69.2 M | 69.2 M | 69.2 M | 109 M | 109 M | 109 M | 109 M | 191 M | 191 M | 191 M | 191 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Pacific Biosciences of California, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Diagnostics research
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
CareDx, Inc
CDNA
|
$ 54.31 | 0.32 % | $ 2.89 B |  USA |
 |
Celcuity
CELC
|
$ 79.99 | 0.12 % | $ 3.74 B | USA |
 |
Co-Diagnostics
CODX
|
$ 1.1 | 1.85 % | $ 1.46 M | USA |
 |
Castle Biosciences
CSTL
|
$ 34.88 | 0.09 % | $ 1.01 B | USA |
 |
Danaher Corporation
DHR
|
$ 221.56 | 0.21 % | $ 158 B | USA |
 |
DexCom
DXCM
|
$ 87.73 | 0.21 % | $ 34.2 B | USA |
 |
Fulgent Genetics
FLGT
|
$ 21.27 | 0.51 % | $ 655 M | USA |
 |
Guardant Health
GH
|
$ 176.31 | 0.27 % | $ 22.1 B | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
$ 163.9 | 0.2 % | $ 12.9 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 522.02 | 0.1 % | $ 42 B | USA |
 |
IQVIA Holdings
IQV
|
$ 267.86 | 0.41 % | $ 46 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 2.75 | 3.33 % | $ 89.2 K | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 303.98 | 0.09 % | $ 25.3 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 99.97 | 0.01 % | $ 6.75 B | USA |
 |
Medpace Holdings
MEDP
|
$ 617.15 | 0.23 % | $ 17.8 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 492.34 | 0.11 % | $ 30.8 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
$ 4.01 | 0.62 % | $ 371 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 6.5 | 4.33 % | $ 5.12 M | USA |
 |
NeoGenomics
NEO
|
$ 18.36 | 0.03 % | $ 2.35 B | USA |
 |
Neogen Corporation
NEOG
|
$ 13.57 | 2.72 % | $ 2.95 B | USA |
 |
Natera
NTRA
|
$ 390.79 | 0.41 % | $ 53.4 B | USA |
 |
Biomerica
BMRA
|
$ 2.61 | 0.36 % | $ 7.61 M | USA |
 |
OPKO Health
OPK
|
$ 1.7 | 0.29 % | $ 1.28 B | USA |
 |
RadNet
RDNT
|
$ 73.21 | 0.11 % | $ 5.5 B | USA |
 |
Sotera Health Company
SHC
|
$ 18.29 | 0.45 % | $ 5.19 B | USA |
 |
Neuronetics
STIM
|
$ 2.88 | 0.21 % | $ 190 M | USA |
 |
Trinity Biotech plc
TRIB
|
$ 7.01 | 0.68 % | $ 2.52 B | Irlanda |
 |
Twist Bioscience Corporation
TWST
|
$ 158.47 | 0.93 % | $ 9.48 B | USA |
 |
Biodesix
BDSX
|
$ 29.29 | 4.05 % | $ 221 M | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.25 | 2.99 % | $ 31.4 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 420.57 | 0.52 % | $ 25 B | USA |
 |
Exagen
XGN
|
$ 8.55 | 1.39 % | $ 184 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.7 | 0.55 % | $ 9.26 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
$ 15.08 | 11.68 % | $ 162 M |  China |
 |
Bioventus
BVS
|
$ 13.61 | 2.55 % | $ 907 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 13.45 | 0.88 % | $ 457 M | Israel |